Successful short-term peg-interferon monotherapy for chronic hepatitis

Apr 08, 2010

The standard duration of interferon therapy for chronic hepatitis C could be shortened according to the virological and clinical status of each patient. A research group in Japan proposed a new concept, "immediate virological response (IVR)", and showed that short-term peg-interferon monotherapy was highly effective for patients with low viral load and IVR. Hepatitis C virus was eliminated in 92.1 percent of patients.

The efficacy of interferon (IFN) therapy depends on the hepatitis C virus (HCV) genotype, pretreatment viral load and early viral kinetics. Thus, IFN therapy must be individualized and optimized according to the virological and clinical status of each patient.

A research article to be published on March 28, 2010 in the addresses this question. Dr. Masumoto and his colleagues at Iizuka Hospital proposed the new concept of early viral kinetics in peg-interferon (PEG-IFN) therapy. They defined the "immediate virological response (IVR)" as the loss of serum HCV RNA 7 days after the first administration of PEG-IFN, and scheduled a 12-week treatment course of PEG-IFN for 38 patients who had low pretreatment HCV RNA load and exhibited IVR. As a result, 35 patients (92.1%) achieved sustained virological response (SVR); the elimination of HCV.

Establishing the minimum and yet sufficient IFN therapy period is essential in terms of financial efficiency and for reducing the risk of adverse events. The results of this study provide an important suggestion which will allow future investigations to optimize the treatment regimen of IFN therapy for chronic , especially for the patients who exhibit fast virological response to IFN. IVR, the new concept proposed in this study, should be a simple and useful indicator of early viral kinetics to predict the high probability of SVR.

Explore further: West Africa's Ebola outbreak prompts changes in I.Coast cuisine

More information: Yada M, Masumoto A, Yamashita N, Motomura K, Koyanagi T, Sakamoto S. Immediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis C. World J Gastroenterol 2010; 16(12): 1506-1511 www.wjgnet.com/1007-9327/full/v16/i12/1506.htm

add to favorites email to friend print save as pdf

Related Stories

Treatment for chronic hepatitis C: A phase II study

Jan 15, 2010

The current standard treatment for chronic hepatitis C with pegylated-interferon (PEG-IFN) and ribavirin is effective in approximately 50%-60% of patients, so that a substantial proportion of patients remain unresponsive. ...

New treatment option for patients with chronic hepatitis C

May 28, 2009

A new combination therapy of daily consensus interferon (CIFN) and ribavirin is effective for some people with chronic hepatitis C (HCV) who do not respond to standard therapy. The treatment works particularly well in interferon-sensitive ...

Discovery could improve hepatitis C treatment

Sep 23, 2009

Walter and Eliza Hall Institute researchers are part of an international team that has discovered a genetic variation that could identify those people infected with hepatitis C who are most likely to benefit ...

Recommended for you

Two expats die of MERS in Saudi commercial hub

21 hours ago

Two foreigners died of MERS in the Saudi city of Jeddah, the health ministry said Saturday, as fears rise over the spreading respiratory virus in the kingdom's commercial hub.

UAE reports 12 new cases of MERS

21 hours ago

Health authorities in the United Arab Emirates have announced 12 new cases of infection by the MERS coronavirus, but insisted the patients would be cured within two weeks.

Filipino tests negative for Middle East virus

Apr 19, 2014

A Filipino nurse who tested positive for the Middle East virus has been found free of infection in a subsequent examination after he returned home, Philippine health officials said Saturday.

User comments : 0

More news stories

Cancer stem cells linked to drug resistance

Most drugs used to treat lung, breast and pancreatic cancers also promote drug-resistance and ultimately spur tumor growth. Researchers at the University of California, San Diego School of Medicine have discovered ...

Making graphene in your kitchen

Graphene has been touted as a wonder material—the world's thinnest substance, but super-strong. Now scientists say it is so easy to make you could produce some in your kitchen.